These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening. Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979 [TBL] [Abstract][Full Text] [Related]
5. Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors. Auld DS; Davis CA; Jimenez M; Knight S; Orme JP Assay Drug Dev Technol; 2015 Jun; 13(5):266-76. PubMed ID: 26107610 [TBL] [Abstract][Full Text] [Related]
6. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Roskoski R Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260 [TBL] [Abstract][Full Text] [Related]
7. Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies. Zhou Y; Zhang N; Qi X; Tang S; Sun G; Zhao L; Zhong R; Peng Y Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301250 [TBL] [Abstract][Full Text] [Related]
13. Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells. Wang C; Wang H; Zheng C; Li B; Liu Z; Zhang L; Yuan L; Xu P ACS Med Chem Lett; 2023 Jan; 14(1):92-102. PubMed ID: 36655129 [TBL] [Abstract][Full Text] [Related]
14. Molecular Dynamics Simulation on the Suppression Mechanism of Phosphorylation to Ser222 by Allosteric Inhibitors Targeting MEK1/2 Kinase. Mudedla SK; Lee H; Kim JJ; Jang SH; Doddareddy MR; Sanam SY; Gundabathula R; Park JJ; Wu S ACS Omega; 2024 Jul; 9(29):31946-31956. PubMed ID: 39072081 [TBL] [Abstract][Full Text] [Related]
15. Allosteric modulators of MEK1: drug design and discovery. Shang J; Lu S; Jiang Y; Zhang J Chem Biol Drug Des; 2016 Oct; 88(4):485-97. PubMed ID: 27115708 [TBL] [Abstract][Full Text] [Related]
16. Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Stockman BJ; Kothe M; Kohls D; Weibley L; Connolly BJ; Sheils AL; Cao Q; Cheng AC; Yang L; Kamath AV; Ding YH; Charlton ME Chem Biol Drug Des; 2009 Feb; 73(2):179-88. PubMed ID: 19207420 [TBL] [Abstract][Full Text] [Related]
17. V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer. Gao Y; Maria A; Na N; da Cruz Paula A; Gorelick AN; Hechtman JF; Carson J; Lefkowitz RA; Weigelt B; Taylor BS; Zhao H; Reis-Filho JS; de Stanchina E; Rosen N; Yao Z; Yaeger R Cancer Discov; 2019 Sep; 9(9):1182-1191. PubMed ID: 31227518 [TBL] [Abstract][Full Text] [Related]
19. In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors. Yari H; Ganjalikhany MR; Sadegh H Comput Biol Chem; 2015 Dec; 59 Pt A():185-98. PubMed ID: 26580563 [TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]